AI Article Synopsis

  • * A survey of 144 HAE patients showed that those receiving lanadelumab experienced fewer attacks and reported a better quality of life compared to those on other long-term therapies.
  • * The findings indicate that patients treated with lanadelumab not only had lower attack frequency but also faced a lower symptomatic impact, suggesting it may be a more effective treatment option.

Article Abstract

Hereditary angioedema (HAE) is a rare genetic disorder characterized by painful, debilitating, and potentially fatal swelling attacks. Lanadelumab is approved as long-term prophylaxis (LTP) in patients with HAE. However, real-world data on LTP use in patients with HAE are limited. To describe clinical characteristics, attack history, and quality of life (QoL) of patients with HAE type I/II who were receiving lanadelumab or other LTPs. Data were drawn from the Adelphi HAE Disease Specific Program, a cross-sectional survey of HAE physicians conducted in the United States from July to November 2021. Physician-reported disease characteristics, HAE attack frequency, and QoL were compared among patients receiving lanadelumab or other LTPs for at least 12 months. Physicians reported data for 144 patients, of whom 29 had received lanadelumab and 115 had received another prophylaxis for at least 12 months. The mean ± standard deviation number of attacks in the previous 12 months was lower among patients receiving lanadelumab than other LTPs (2.3 ± 3.1 versus 3.4 ± 2.8, respectively; p = 0.075). Although both groups had similar current disease activity and severity, more patients receiving lanadelumab versus other LTPs had high disease activity (51.7% versus 12.5%, respectively; p < 0.0001) and disease severity rated as severe (51.7% versus 16.1%, respectively; p = 0.0001) at diagnosis. Physicians reported that more patients who received lanadelumab had good or very good QoL (72.4%) than those receiving other LTPs (36.5%) (p = 0.003). Analysis of these findings suggests lower attack frequency, lower symptomatic impact, and better QoL in patients treated with lanadelumab than another prophylaxis in a real-world setting.

Download full-text PDF

Source
http://dx.doi.org/10.2500/aap.2024.45.240046DOI Listing

Publication Analysis

Top Keywords

receiving lanadelumab
16
patients hae
12
lanadelumab ltps
12
patients receiving
12
patients
8
hereditary angioedema
8
lanadelumab versus
8
ltp patients
8
disease activity
8
lanadelumab
7

Similar Publications

Hereditary angioedema in children: Review and practical perspective for clinical management.

Pediatr Allergy Immunol

December 2024

French National Reference Center for Angioedema (CREAK), Center of Excellence and Reference (ACARE), Internal Medicine Department, Grenoble Alpes University Hospital, Grenoble, France.

Background: Hereditary angioedema (HAE) in children has specific features and requires multidisciplinary management.

Methods: We performed a literature search and underwent in-depth discussions to provide practical tools for physicians.

Results: HAE is a rare, life-threatening genetic disorder.

View Article and Find Full Text PDF
Article Synopsis
  • Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
  • There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
  • There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
View Article and Find Full Text PDF
Article Synopsis
  • Cardiovascular diseases are the leading cause of death in patients with hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH), often exacerbated by long-term treatments like attenuated androgens that can increase cardiovascular risk.
  • A case study of a 56-year-old HAE-C1INH patient with numerous health issues, including kidney impairment and hypertension, showcased a successful transition from traditional androgen therapy to the modern treatment, lanadelumab, starting in 2020.
  • After beginning lanadelumab, the patient saw no angioedema attacks, experienced a decrease in cardiovascular risk factors like cholesterol and body mass index, and improved overall health outcomes, indicating this treatment's effectiveness and safety.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!